Pulished Date August, 2019
ID: 1597
Share on
Share on

Latin America Orphan Drugs Market Research Report – Segmented By Type, Therapeutic, Country (Mexico, Brazil, Argentina, Chile and Rest of Latin America) - Industry Analysis, Size, Share, Growth, Trends, Forecast | 2019 – 2024

Pulished: August, 2019
ID: 1597
Pages: 145

LATAM Orphan Drugs Market Size & Growth (2019 - 2024)

The size of the Orphan Drugs Market in Latin America was worth USD 13.2 billion in 2019 and estimated to be growing at a CAGR of 7.38%, to reach USD 18.85 billion by 2024.

Rising support from the government through investments in the development of specified drugs for rare diseases with high quality is the major driving factor for the market to grow. Increasing incidences of rare diseases like cancer and neurodegenerative diseases are propelling the demand of Latin America orphan drugs market. These drugs are manufactured specifically according to the rare diseases which are also multiplying the shares of the market. In addition, growing prevalence to have effective treatment procedures at any cost is escalating the demand of the market. Awareness over the availability of different treatment procedures for every disease through campaigns and digital advertisements is promoting the growth rate of the market. Early diagnosis of a disease by most of the people is also leveling up the demand of the orphan drugs market in Latin America.

However, the dearth of skilled professionals in manufacturing the latest drugs with a specific formula is slowly hindering the growth rate of the market. Orphan drugs are a bit expensive when compared with normal medicines and this remains a challenging factor for the market players. Strict rules by the government over pharmaceutical companies to release high-quality products are impeding the demand of the market. Lack of standardization is also restricting the demand of the market.

Advanced technology is playing a crucial part in introducing innovative products in the medical sector which is lucrative to improve growth opportunities for the market. The rising geriatric population is ascribed to outshine the demand of the market. Growing knowledge over the combination therapy approaches is accelerating the growth rate of the Latin America orphan drugs market. Increasing demand to increase the production of orphan drugs along with an increasing number of patients with various diseases is broadening the demand of the market. Furthermore, changes in the schemes by the government in concern towards people’s health are leveling up the growth rate of this market.

This research report has been segmented & sub-segmented into the following categories:

  • By Type: Biological and Non-Biological
  • By Therapeutic: Hematology, Neurology, Oncology and Others
  • By Country: Mexico, Brazil, Argentina, Chile and Rest of Latin America

On the basis of type, the Non-Biological Orphan Drugs lead the market with more than 60% of the market share.

On the basis of Therapeutics, Neurology accounts for almost 40% of the entire market share.

Regionally, Orphan drug access in Latin America will continue to rise over the long-term, propelled by the need to promote the marketing and state procurement of these high-value drugs. Multinational drugmakers will profit from the growing patient demand, which will create further commercial prospects in years to come. However, over the short-term, access will remain limited as the region's larger economic slump confines overall spending capabilities.

Promising companies operating in the LATAM Orphan Drugs Market profiled in this report are Novartis, GlaxoSmithKline, Roche, Alexion, Sanofi, Bristol Myers Squibb, Pfizer, Vertex, Celgene, and Merck.

 

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Type                              

                                5.1.1 Introduction           

                                5.1.2 Biological

                                5.1.3 Non Biological        

                                5.1.4  Y-o-Y Growth Analysis, By Type     

                                5.1.5  Market Attractiveness Analysis, By Type   

                                5.1.6  Market Share Analysis, By Type    

                5.2 Therapeutic                                

                                5.2.1 Haematology         

                                5.2.2 Neurology

                                5.2.3 Oncology 

                                5.2.4 Others      

                                5.2.5  Y-o-Y Growth Analysis, By Therapeutic       

                                5.2.6  Market Attractiveness Analysis, By Therapeutic     

                                5.2.7  Market Share Analysis, By Therapeutic      

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Type

                                                6.1.3.3 By Therapeutic

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Type

                                                6.1.4.3 By Therapeutic

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Type

                                                6.1.5.3 By Therapeutic

                6.2 Brazil                             

                6.3 Mexico                         

                6.4 Rest of Latin America                             

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Novartis                       

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 GlaxoSmithKline                      

                8.3 Roche                           

                8.4 Alexion                        

                8.5 Sanofi                           

                8.6 Bristol Myers Squibb                              

                8.7 Pfizer                            

                8.8 Vertex                          

                8.9 Celgene                       

                8.10 Merck                        

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                               

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Latin America Orphan Drugs Market By Type, From 2019 - 2024 ( USD Billion )
  2. Latin America Biological Market By Region, From 2019 - 2024 ( USD Billion )
  3. Latin America Non Biological Market By Region, From 2019 - 2024 ( USD Billion )
  4. Latin America Orphan Drugs Market By Therapeutic, From 2019 - 2024 ( USD Billion )
  5. Latin America Haematology Market By Region, From 2019 - 2024 ( USD Billion )
  6. Latin America Neurology Market By Region, From 2019 - 2024 ( USD Billion )
  7. Latin America Oncology Market By Region, From 2019 - 2024 ( USD Billion )
  8. Latin America Other therapeutics Market By Region, From 2019 - 2024 ( USD Billion )
  9. Brazil Orphan Drugs Market By Type, From 2019 - 2024 ( USD Billion )
  10. Brazil Orphan Drugs Market By Therapeutic, From 2019 - 2024 ( USD Billion )
  11. Argentina Orphan Drugs Market By Type, From 2019 - 2024 ( USD Billion )
  12. Argentina Orphan Drugs Market By Therapeutic, From 2019 - 2024 ( USD Billion )
  13. Mexico Orphan Drugs Market By Type, From 2019 - 2024 ( USD Billion )
  14. Mexico Orphan Drugs Market By Therapeutic, From 2019 - 2024 ( USD Billion )
  15. Rest of Latin America Orphan Drugs Market By Type, From 2019 - 2024 ( USD Billion )
  16. Rest of Latin America Orphan Drugs Market By Therapeutic, From 2019 - 2024 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample